



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: **Meade et al.**

Art Unit No.: **1632**

Application No.: **10/081,400**

Examiner: **Joseph T. Woitach**

Filed: **February 20, 2002**

For: **ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION**

Attorney Docket Number: **GTC-6D**

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


AMENDMENT AFTER FINAL AND TRANSMITTAL OF SEQUENCE LISTING

Enclosed is a diskette which contains a computer readable form of the revised Sequence Listing filed herewith. It is Applicant's understanding that the Sequence Listing complies with the requirements of 37 CFR §§ 1.821(f) and (g); and 1.824. The material on this diskette is identical in substance to the sequences appearing or noted on page 3 of the amended specification which is submitted herewith. Furthermore, Applicant hereby states that the information recorded in computer readable form is identical to the written sequence listing filed herewith as required by § 1.824(f) and does not contain any new matter as required under 37 CFR § 1.821(g).

Date: 12/21/05


Respectfully Submitted,

By:


Byron V. Olsen, Reg. No. 42,960
ATTORNEY FOR APPLICANTS
GTC Biotherapeutics, Inc.
175 Crossing Blvd., Suite 410
Framingham, MA 01702
Tel. # (508) 370-5150
Fax # (508) 370-3797

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited on Dec 22, 2005 with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to: Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Dawn C. Greenaway